#NACFC2022 – Smoking Exposure Can Limit Effectiveness of Kalydeco
Exposure to tobacco smoke may reduce the effectiveness of Kalydeco (ivacaftor), a CFTR modulator that is widely approved to treat cystic fibrosis (CF) caused by specific mutations. That’s according to data shared by Gabriela Oates, PhD, at the 2022 North American Cystic Fibrosis Conference, taking place Nov. 3–5…